// App-Quantinova.ai

1566 : Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch

Researchers

Presenter

  • Vance MacDonald

Principal Investigators

  • Xin Ying Lee

  • Alexandre Caillaud

  • Maria Luckevich

  • Anthony Bentley

Medical Centers

  • Novo Nordisk Canada Inc, Mississauga, Canada

  • Novo NordiskA/S, Soborg, Denmark

  • Mtech Access, Bicester, United Kingdom

Locations

  • Canada

  • Denmark

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

  • Tuberculosis

Biomarkers

  • N/A

Drug/Treatment

  • N9-GP

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved